Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Bio-Rad Laboratories, Inc.: Strengths and Weaknesses

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Bio-Rad Laboratories, Inc.
  • The company is in a robust financial situation considering its net cash and margin position.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses: Bio-Rad Laboratories, Inc.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • With an expected P/E ratio at 45.56 and 44.54 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

Bio-Rad Laboratories, Inc. SectorGermany

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

Bio-Rad Laboratories, Inc. SectorGermany

Global Valuation

-

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Bio-Rad Laboratories, Inc. SectorGermany

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Bio-Rad Laboratories, Inc. SectorGermany

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Bio-Rad Laboratories, Inc. SectorGermany

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
10.06B
BBB
-
177B
BBB
118B
BBB
60.78B
AA
49.53B
A
48.29B
AAA
32.96B
BBB
28.94B
A
25.48B
AAA
21.77B
BBB
Average 57.34B
A
Weighted average by Cap.
A
  1. Stock Market
  2. Stocks
  3. BIO Stock
  4. BUWA Stock
  5. Ratings Bio-Rad Laboratories, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!